J Holst

Summary

Affiliation: Norwegian Institute of Public Health
Country: Norway

Publications

  1. ncbi request reprint Bordetella pertussis can act as adjuvant as well as inhibitor of immune responses to non-replicating nasal vaccines
    Anita Haugan
    Division of Infectious Disease Control, Norwegian Institute of Public Health, P O Box 4404 Nydalen, N 0403 Oslo, Norway
    Vaccine 22:7-14. 2003
  2. ncbi request reprint Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them
    Johan Holst
    Department of Bacteriology and Immunology, Norwegian Institute of Public Health, Oslo, Norway
    Hum Vaccin 3:290-4. 2007
  3. doi request reprint Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis
    Johan Holst
    Department of Bacteriology and Immunology, Norwegian Institute of Public Health, Oslo, P O Box 4404 Nydalen, Oslo NO 0403, Norway
    Vaccine 27:B3-12. 2009
  4. ncbi request reprint The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease
    Johan Holst
    Norwegian Institute of Public Health, Oslo, Norway
    Vaccine 23:2202-5. 2005
  5. ncbi request reprint Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease
    J Holst
    Division of Infectious Disease Control, Norwegian Institute of Public Health, PO Box 4404, Nydalen, Oslo N 0403, Norway
    Vaccine 21:734-7. 2003
  6. pmc Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine
    F Oftung
    Department of Vaccinology, National Institute of Public Health, Institute of Pharmacy, University of Oslo, Oslo, Norway
    Infect Immun 67:921-7. 1999
  7. pmc Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans
    B Haneberg
    Department of Vaccinology, National Institute of Public Health, Oslo, Norway
    Infect Immun 66:1334-41. 1998
  8. ncbi request reprint Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine
    A K Berstad
    Department of Vaccinology, National Institute of Public Health, P O Box 4404 Torshov, N 0403, Oslo, Norway
    Vaccine 18:2323-30. 2000
  9. ncbi request reprint Outer membrane vesicles from group B meningococci are strongly immunogenic when given intranasally to mice
    R Dalseg
    Department of Vaccinology, National Institute of Public Health, Oslo, Norway
    Vaccine 17:2336-45. 1999
  10. ncbi request reprint Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease
    A Aase
    Division of Infectious Disease Control, Norwegian Institute of Public Health, P O Box 4404 Nydalen, NO 0403 Oslo, Norway
    Vaccine 21:2042-51. 2003

Collaborators

Detail Information

Publications19

  1. ncbi request reprint Bordetella pertussis can act as adjuvant as well as inhibitor of immune responses to non-replicating nasal vaccines
    Anita Haugan
    Division of Infectious Disease Control, Norwegian Institute of Public Health, P O Box 4404 Nydalen, N 0403 Oslo, Norway
    Vaccine 22:7-14. 2003
    ..The inhibition of these responses may thus depend on Bp and CT themselves being strongly immunogenic, and competing with INV for the functional capacity of the mucosal immune system...
  2. ncbi request reprint Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them
    Johan Holst
    Department of Bacteriology and Immunology, Norwegian Institute of Public Health, Oslo, Norway
    Hum Vaccin 3:290-4. 2007
    ..Defining criteria for establishing and revising such strain collections is currently ongoing and will be a key element in developing and evaluating new protein based vaccines in the time to come...
  3. doi request reprint Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis
    Johan Holst
    Department of Bacteriology and Immunology, Norwegian Institute of Public Health, Oslo, P O Box 4404 Nydalen, Oslo NO 0403, Norway
    Vaccine 27:B3-12. 2009
    ..The desire to have a global vaccine strategy that enables susceptible individuals to be protected against all the relevant serogroups of meningococcal disease may become a reality...
  4. ncbi request reprint The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease
    Johan Holst
    Norwegian Institute of Public Health, Oslo, Norway
    Vaccine 23:2202-5. 2005
    ..This assumption is based on the epidemiological observation that meningococcal outbreaks in Africa are clonal and are strikingly stable regarding their phenotypic characteristics...
  5. ncbi request reprint Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease
    J Holst
    Division of Infectious Disease Control, Norwegian Institute of Public Health, PO Box 4404, Nydalen, Oslo N 0403, Norway
    Vaccine 21:734-7. 2003
    ..Measurements of SBA are likely to be useful for evaluating various upcoming formulations and improvements of immunization regimens for OMV vaccines...
  6. pmc Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine
    F Oftung
    Department of Vaccinology, National Institute of Public Health, Institute of Pharmacy, University of Oslo, Oslo, Norway
    Infect Immun 67:921-7. 1999
    ..In conclusion, we have shown that it is possible to induce antigen-specific T-cell responses in humans by intranasal administration of a meningococcal OMV vaccine without adjuvant...
  7. pmc Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans
    B Haneberg
    Department of Vaccinology, National Institute of Public Health, Oslo, Norway
    Infect Immun 66:1334-41. 1998
    ....
  8. ncbi request reprint Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine
    A K Berstad
    Department of Vaccinology, National Institute of Public Health, P O Box 4404 Torshov, N 0403, Oslo, Norway
    Vaccine 18:2323-30. 2000
    ..This demonstrates that intranasal administration of a non-proliferating bacterial vaccine without any additional mucosal adjuvant can induce vaccine-specific T cell responses related to mucosal IgA secretion...
  9. ncbi request reprint Outer membrane vesicles from group B meningococci are strongly immunogenic when given intranasally to mice
    R Dalseg
    Department of Vaccinology, National Institute of Public Health, Oslo, Norway
    Vaccine 17:2336-45. 1999
    ..Nasal vaccines may thus be favorably combined with parenteral vaccines...
  10. ncbi request reprint Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease
    A Aase
    Division of Infectious Disease Control, Norwegian Institute of Public Health, P O Box 4404 Nydalen, NO 0403 Oslo, Norway
    Vaccine 21:2042-51. 2003
    ....
  11. ncbi request reprint Immunisation schedules for non-replicating nasal vaccines can be made simple by allowing time for development of immunological memory
    Hilde Bakke
    Division of Infectious Disease Control, Norwegian Institute of Public Health, PO Box 4404 Nydalen, NO 0403 Oslo, Norway
    Vaccine 22:2278-84. 2004
    ..In order to secure adequate systemic responses by a minimum of doses, nasal vaccines should therefore be given at intervals longer than 4 weeks, in harmony with the intervals recommended for injectable vaccines...
  12. ncbi request reprint Outer membrane vesicles from Neisseria meningitidis: effects on tissue factor and plasminogen activator inhibitor-2 production in human monocytes
    M R Mirlashari
    Research Forum, Ullevaal University Hospital, Oslo, Norway
    Thromb Res 102:375-80. 2001
    ....
  13. ncbi request reprint Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity
    H Bakke
    Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway
    Scand J Immunol 63:223-31. 2006
    ....
  14. ncbi request reprint Bacteria-derived particles as adjuvants for non-replicating nasal vaccines
    B Haneberg
    Department of Vaccinology, National Institute of Public Health, P O Box 4404 Nydalen, N 0403, Oslo, Norway
    Adv Drug Deliv Rev 51:143-7. 2001
    ..Bacteria-derived particles in nasal vaccines may thus serve as an alternative adjuvant to derivatives of cholera toxin or the heat-labile toxin from E. coli...
  15. ncbi request reprint Outer membrane vesicles from Neisseria meningitidis
    Mohammad Reza Mirlashari
    Research Forum, Ullevaal University Hospital, Oslo, Norway
    APMIS 110:193-204. 2002
    ....
  16. ncbi request reprint Can nonliving nasal vaccines be made to work?
    Bjørn Haneberg
    Division for Infectious Disease Control, Norwegian Institute of Public Health, Nydalen, Oslo
    Expert Rev Vaccines 1:227-32. 2002
    ..This will depend on refined immunization schedules to benefit from immunological memory and on formulations to make the vaccines more accessible to the immune system by way of mucosal adjuvants or immune modulators...
  17. ncbi request reprint Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks
    Muhamed Kheir Taha
    Vaccine 25:2537-8. 2007
  18. ncbi request reprint Contributions of the Norwegian Institute of Public Health to the development of vaccines against serogroup B meningococcal disease
    Einar Rosenqvist
    Vaccine 25:965-6. 2007
  19. ncbi request reprint A non-living nasal influenza vaccine can induce major humoral and cellular immune responses in humans without the need for adjuvants
    Helvi Holm Samdal
    Department of Microbiology, Buskerud Hospital Trust, Drammen, and Haukeland University Hospital, Bergen, Norway
    Hum Vaccin 1:85-90. 2005
    ..An influenza vaccine made as a simple particulate formulation of inactivated virus, and given repeatedly onto the nasal mucosa, may thus be an attractive alternative to currently available vaccines...